This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TOCA vs. KROS, QURE, SBTX, ARVN, PRTA, SVRA, URGN, KURA, CRMD, and GHRSShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Keros Therapeutics (KROS), uniQure (QURE), Silverback Therapeutics (SBTX), Arvinas (ARVN), Prothena (PRTA), Savara (SVRA), UroGen Pharma (URGN), Kura Oncology (KURA), CorMedix (CRMD), and GH Research (GHRS). These companies are all part of the "medical" sector. Tocagen vs. Keros Therapeutics uniQure Silverback Therapeutics Arvinas Prothena Savara UroGen Pharma Kura Oncology CorMedix GH Research Tocagen (NASDAQ:TOCA) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Do institutionals & insiders have more ownership in TOCA or KROS? 21.4% of Tocagen shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 10.9% of Tocagen shares are owned by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer TOCA or KROS? In the previous week, Keros Therapeutics had 8 more articles in the media than Tocagen. MarketBeat recorded 8 mentions for Keros Therapeutics and 0 mentions for Tocagen. Keros Therapeutics' average media sentiment score of 1.46 beat Tocagen's score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Tocagen Neutral Keros Therapeutics Positive Which has better earnings and valuation, TOCA or KROS? Tocagen has higher earnings, but lower revenue than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTocagen$40K4,161.91-$63.52M-$2.69-2.59Keros Therapeutics$3.55M162.36-$152.99M-$5.01-2.84 Do analysts recommend TOCA or KROS? Keros Therapeutics has a consensus price target of $40.33, indicating a potential upside of 183.84%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Keros Therapeutics 0 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.57 Is TOCA or KROS more profitable? Keros Therapeutics has a net margin of -27,890.94% compared to Tocagen's net margin of -176,433.34%. Keros Therapeutics' return on equity of -41.74% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets Tocagen-176,433.34% -327.74% -111.87% Keros Therapeutics -27,890.94%-41.74%-38.42% Which has more volatility and risk, TOCA or KROS? Tocagen has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Does the MarketBeat Community favor TOCA or KROS? Tocagen received 178 more outperform votes than Keros Therapeutics when rated by MarketBeat users. However, 69.89% of users gave Keros Therapeutics an outperform vote while only 66.03% of users gave Tocagen an outperform vote. CompanyUnderperformOutperformTocagenOutperform Votes24366.03% Underperform Votes12533.97% Keros TherapeuticsOutperform Votes6569.89% Underperform Votes2830.11% SummaryKeros Therapeutics beats Tocagen on 14 of the 18 factors compared between the two stocks. Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$166.48M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-2.947.1422.1418.39Price / Sales4,161.91238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book15.476.266.664.18Net Income-$63.52M$142.48M$3.21B$247.71M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$6.96+15.0%N/A+740.4%$166.48M$40,000.00-2.9477KROSKeros Therapeutics3.0524 of 5 stars$13.09+2.7%$40.33+208.1%-74.4%$530.96M$3.55M-2.51100Positive NewsQUREuniQure2.3524 of 5 stars$9.65+5.2%$38.80+302.1%+212.7%$521.84M$27.12M-1.95500SBTXSilverback TherapeuticsN/A$14.47+3.0%N/A+74.1%$521.76MN/A-5.9883High Trading VolumeARVNArvinas3.3036 of 5 stars$7.58+2.4%$34.53+355.6%-71.9%$521.29M$263.40M-2.74420High Trading VolumePRTAProthena2.9768 of 5 stars$9.59-3.5%$55.00+473.5%-53.1%$516.20M$135.16M-4.17130Analyst RevisionSVRASavara2.3205 of 5 stars$2.93+1.0%$8.83+201.5%-22.9%$505.82MN/A-6.81N/APositive NewsURGNUroGen Pharma4.3296 of 5 stars$10.75+1.4%$38.20+255.3%-28.9%$495.51M$90.40M-3.41200News CoverageKURAKura Oncology4.3099 of 5 stars$6.03+3.1%$25.50+322.9%-65.7%$486.95M$53.88M-2.56130Upcoming EarningsPositive NewsGap DownHigh Trading VolumeCRMDCorMedix2.6233 of 5 stars$7.40+3.8%$14.50+95.9%+71.7%$482.35M$43.47M-9.1430GHRSGH Research2.9835 of 5 stars$8.99-1.1%$30.86+243.2%-14.3%$467.73MN/A-11.3810Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Keros Therapeutics Alternatives uniQure Alternatives Silverback Therapeutics Alternatives Arvinas Alternatives Prothena Alternatives Savara Alternatives UroGen Pharma Alternatives Kura Oncology Alternatives CorMedix Alternatives GH Research Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TOCA) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TOCA Stock Free TOCA Stock Alerts